Filing history

1. 8-K2026-08-19

   Source ↗

   No parsed narrative for this filing.

2. 8-K2026-08-19

   Source ↗

   No parsed narrative for this filing.

3. 8-K2026-08-05

   Source ↗

   This 8-K is purely a financing event, not an operating update. Twist Bioscience priced an upsized common stock offering of 3,125,000 shares at $96.00 per share and, after the underwriters exercised their option for 468,750 additional shares in full on August 5, 2026, expects net proceeds of approximately $327.1 million after underwriting discounts, commissions and estimated offering expenses, with closing expected on or about August 6, 2026 under the company's automatic shelf registration statement on Form S-3 (No. 333-296897). There is no MD&A, guidance, backlog/orders, debt or leverage, capex or strategic-priority content in the filing — the only risk disclosure is standard forward-looking-statement language pointing to the risk factors in the Form 10-K filed November 17, 2025, which remains the substantive risk source. For an investor, the operative facts are the roughly $327 million gross-up of the balance sheet at a $96.00 per-share price (the deal was upsized from an announced $250.0 million to $300.0 million, suggesting solid demand) alongside dilution of about 3.59 million shares; because the filing discloses no use of proceeds, the capital allocation rationale must be sourced elsewhere, and nothing here speaks to the underlying business trajectory.

   Capital allocationOn August 4, 2026 the Company entered into an underwriting agreement with Goldman Sachs & Co. LLC, William Blair & Company, L.L.C., Leerink Partners LLC and Guggenheim Securities, LLC to issue and sell 3,125,000 shares of common stock at a public offering price of $96.00 per share, with the underwriters exercising in full (on August 5, 2026) their 30-day option for 468,750 additional shares at $96.00 per share. Net proceeds, including the option shares, are expected to be approximately $327.1 million after deducting underwriting discounts and commissions and estimated offering expenses. The offering was upsized from an announced $250.0 million to $300.0 million and is made under the Company's automatic shelf registration statement on Form S-3 (No. 333-296897); the filing does not disclose a stated use of proceeds.

   Key risks

   • Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from those expressed or implied; the filing directs readers to the risk factors in the Company's Annual Report on Form 10-K filed with the SEC on November 17, 2025.
   • The offering remains subject to customary closing conditions and the expected approximately $327.1 million of net proceeds is a forward-looking expectation rather than a completed result.
4. 8-K2026-08-03

   Source ↗

   No parsed narrative for this filing.

5. 10-Q2026-08-03

   Source ↗

   Twist's fiscal Q3 2026 shows a business with genuine top-line momentum but deteriorating operating leverage: revenue rose 23% to $118.4 million (nine months +20% to $332.8 million) as DNA synthesis and protein solutions jumped 39% and genes shipped rose 56% to roughly 369,000, yet SG&A climbed 27% to $80.7 million and the quarterly operating loss widened 20.5% to $36.3 million, leaving the company reliant on revenue mix to defend a 52.8% gross margin that slipped on 'customer mix' even as the nine-month margin improved 1.6 points to 52.1%. The reported numbers are noisy because the year-ago quarter included a $48.8 million gain on the DNA data storage sale (turning a $35.1 million loss into $20.4 million of income) and the current nine-month period carries $7.2 million of litigation settlement costs tied to the securities class action, offset by a probable ~$16.3 million insurance recovery with final court approval expected November 18, 2026. The balance sheet is entirely equity-funded — no debt, $166.8 million of cash and short-term investments against a $1,429.2 million accumulated deficit and $93.6 million of operating lease liabilities — and the filing offers no guidance beyond an assertion that liquidity covers 'more than 12 months' and an expectation that SG&A moderates in Q4 FY26 on cost-saving initiatives, with a fresh $200 million ATM providing optionality. With only $21.9 million of unsatisfied performance obligations, the thesis rests on whether accelerating protein-solutions and NGS demand converts into durable gross margin and operating leverage rather than continued SG&A creep.

   GuidanceNo revenue or earnings guidance is provided. Management states only that it 'expect[s] selling, general and administrative expense to moderate in the fourth quarter of fiscal 2026 resulting from a number of cost saving initiatives,' and that current cash, cash equivalents and short-term investments plus anticipated cash flow from operations 'will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this Quarterly Report on Form 10-Q.'

   Outlook / toneManagement provides no revenue, margin or earnings guidance and frames the outlook almost entirely in liquidity and cost terms. In the filing's own language, the company 'believe[s] our current cash, cash equivalents and short-term investments and anticipated cash flow from operations will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this Quarterly Report on Form 10-Q,' while cautioning that 'if we need to obtain additional financing to fund operations beyond this period, there can be no assurance that we will be successful in raising additional financing on terms that are acceptable to us.' The only near-term operating expectation offered is that SG&A 'will moderate in the fourth quarter of fiscal 2026 resulting from a number of cost saving initiatives.' Management states that profitability 'will depend heavily on the success of our existing products and the development and commercialization of additional products in the therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners industries as well as leveraging our investment in our manufacturing infrastructure,' and that it 'take[s] a long-term view in growing and scaling our business' and 'regularly review[s] acquisition and investment opportunities.'

   Strategic priorities

   • Extend the proprietary silicon-based DNA synthesis platform beyond DNA synthesis into an integrated portfolio including synthetic genes, NGS applications, sample preparation tools, antibody libraries, synthetic RNA and biologics discovery services.
   • Grow the two reporting product lines, DNA synthesis and protein solutions and NGS applications, supported by 'headcount additions and investments in our commercial organization and corporate infrastructure.'
   • Pursue margin expansion and cost control through continuous process improvement, automation and capacity expansion, with SG&A expected to moderate in Q4 FY26 via cost saving initiatives.
   • Expand biologics discovery capabilities through the February 2026 Invenra transactions: a co-exclusive, royalty-bearing license to the B-Body bispecific antibody discovery platform and a simultaneous 6.24% fully-diluted equity interest, representing a combined $33.8 million commitment settled in cash and common stock.
   • Consolidate other South San Francisco offices into a single location under the November 2025 lease amendment.
   • Preserve financing flexibility through a newly established $200.0 million at-the-market equity offering program and a new Form S-3ASR shelf registration statement filed June 18, 2026.

   Capex plansThe company had $12.2 million in commitments for capital expenditures as of June 30, 2026. Nine-month purchases of property and equipment were $27.6 million versus $15.6 million in the prior-year period, and construction in progress of $19.5 million 'mainly represents equipment costs, leasehold improvement costs and internal use software development costs.' The November 13, 2025 South San Francisco lease amendment adds approximately 33,000 square feet (commencing September 1, 2026, with an option to expand by a further ~33,000 square feet on or before December 31, 2026), carries a landlord tenant-improvement allowance of approximately $24.4 million, and is expected to require future cash commitments of $11.6 million through June 30, 2036.

   Capital allocationPrimary uses of capital are 'compensation and related expenses, manufacturing costs, laboratory and related supplies, legal and other regulatory expenses and general overhead costs, including facilities costs and capital expenditures.' In June 2026 the company established a $200.0 million at-the-market equity offering program with TD Securities (USA) LLC at up to 3.0% commission; no shares had been sold and the full $200.0 million remained available as of June 30, 2026. Nine-month financing inflows were $8.2 million, comprising $5.9 million of stock option exercises and $2.4 million of ESPP issuances; the only repurchases were $16 thousand of shares withheld for income tax withholding. The $33.8 million Invenra commitment required only $5.0 million of cash, with $28.8 million settled or to be settled through common stock issuance ($10.0 million issued at closing plus $5.0 million contingently issuable on technology transfer for the license, and $13.8 million for the Series B investment), limiting the cash impact on liquidity. No dividends are mentioned.

   BacklogThe aggregate transaction price allocated to performance obligations unsatisfied as of June 30, 2026 was $21.9 million, of which the company 'expects to recognize revenues of $16.3 million over the next twelve months.' Contract balances were $6.2 million of contract assets, $6.5 million of current contract liabilities and $5.7 million of non-current contract liabilities at June 30, 2026.

   Debt / leverageNo borrowings or credit facility debt are disclosed; the company's capital structure is equity-funded. Total liabilities were $226.7 million against total stockholders' equity of $445.7 million. Non-equity obligations consist primarily of operating lease liabilities of $93.6 million ($8.6 million current, $85.0 million non-current, with total minimum lease payments of $147.2 million), a $15.0 million 'liability related to the sale of future revenue' carried unchanged from September 30, 2025, and a $5.0 million ASC 480 liability for common stock contingently issuable upon successful completion of the Invenra technology transfer. Liquidity comprised $117.4 million of cash and cash equivalents and $49.4 million of short-term investments ($166.8 million total).

   Risk-factor changesNo new or revised risk factors are presented in this Form 10-Q. Item 1A directs readers to the risk factors contained in Part I, Item 1A of the Annual Report on Form 10-K filed with the SEC on November 17, 2025, and the forward-looking statements section lists the same categories of risks (revenue growth, financing needs, competition, IP protection, IT security, personnel retention, regulation and macro conditions).

   MD&A highlights

   • Q3 FY26 revenues rose 23% to $118.4 million from $96.1 million, and nine-month revenues rose 20% to $332.8 million, driven by DNA synthesis and protein solutions (up 39% in Q3, 31% for nine months) and NGS applications (up 12% in Q3, 11% for nine months).
   • Q3 gross margin decreased 0.6 percentage points to 52.8% 'primarily due to customer mix'; nine-month gross margin increased 1.6 points to 52.1% on higher revenues and 'cost savings realized through continuous process improvement initiatives partially offset by investments for capacity expansion and automation.'
   • Loss from operations increased 20.5% to $36.3 million in Q3 and 8.2% to $115.0 million for the nine months, 'primarily due to an increase in selling, general and administrative expenses and litigation settlement costs, net of recoveries, offset by increases in both revenues and gross profit and a decrease in research and development expenses.'
   • SG&A rose 27% to $80.7 million in Q3 (and 24% to $226.5 million for nine months) on headcount additions and 'investments in our commercial organization and corporate infrastructure to support the continued growth of the business.'
   • R&D was flat at $18.0 million in Q3 and fell 13% to $54.8 million for nine months, with decreases 'largely attributable to the sale of our DNA data storage business in fiscal year 2025.'
   • Volume metrics: genes shipped rose 56% to approximately 369,000 in Q3 and 41% to approximately 940,000 for nine months; customers were approximately 2,664 versus 2,484 a year earlier, and the company says it serves 'more than 3,800 customers annually.'
   • Net loss was $35.1 million in Q3 versus net income of $20.4 million a year ago, which included the $48.8 million gain on the DNA data storage sale; nine-month net loss was $109.6 million versus $50.5 million.
   • Litigation settlement costs, net of recoveries, were $7.2 million for the nine months; the company determined recovery of approximately $16.3 million from liability insurers is probable and recorded a corresponding insurance receivable.
   • Nine-month net cash used in operating activities increased 15.2% to $41.3 million from $35.8 million; purchases of property and equipment were $27.6 million versus $15.6 million.

   Key risks

   • Ability to increase revenues and the revenue growth rate, and to accurately estimate capital requirements and needs for additional financing.
   • Competition, rapid technological change, and ability to protect intellectual property including the proprietary DNA synthesis platform, plus costs of defending IP infringement and other claims.
   • Ability to manage growth and maintain and improve operational efficiency, cost control and gross margin as the company scales, and to leverage its investment in manufacturing infrastructure.
   • Pending securities class action settlement of approximately $17.1 million (preliminary approval granted July 17, 2026; final approval hearing November 18, 2026) and the consolidated derivative action settlement under which insurers pay approximately $1.0 million in plaintiffs' counsel fees and the company adopts certain governance policies.
   • Exposure to unconsolidated variable interest entities: maximum exposure of $90.0 million, including $68.1 million of investment in equity securities (of which $53.9 million is a related party), a $20.0 million asset acquisition purchase consideration and a $5.0 million stock issuance liability.
   • Dependence on a broad set of external factors cited in the forward-looking statements, including IT system disruption or breach, changes in government regulation, adverse economic and market conditions, catastrophic events or public health emergencies, and ability to attract and retain key personnel.
   • International expansion and compliance with evolving regulatory requirements in the European Union and other key markets.
6. 8-K2026-05-04

   Source ↗

   No parsed narrative for this filing.

7. 10-Q2026-05-04

   Source ↗

   Twist delivered a genuinely improving top line in fiscal Q2 2026 -- revenue up 19.3% to $110.7 million (H1 +18.1% to $214.4 million) with gross margin up roughly 200-280 bps to ~51.6-51.8% on process-improvement savings, a 28% surge in DNA synthesis and protein solutions, and therapeutics emerging as the largest industry at $40.8 million (37% of revenue). The offset is that the operating loss still widened 10.4% to $45.9 million and net loss was $44.0 million ($74.5 million H1), as SG&A rose 19-22% for commercial and infrastructure build-out while R&D fell 18-19% mostly from the FY2025 DNA data storage divestiture, and H1 operating cash use grew 23.1% to $42.4 million. The balance sheet is unlevered with $171.7 million of cash plus short-term investments against a $1,394.1 million accumulated deficit, and management calls liquidity sufficient for more than 12 months; capital is being directed at facilities (a 33,000 sq ft South San Francisco lease expansion with a $24.4 million TI allowance and $15.7 million of capex commitments) and the Invenra bispecific antibody platform deal ($33.8 million total commitment, only $5.0 million in cash). The principal near-term swing factor is the ~$17.1 million securities class action settlement in principle (net $7.2 million after a $14.9 million probable insurance recovery) with derivative suits stayed, and management's sole forward marker is that SG&A should 'moderate' in H2 FY2026 -- leaving the core investor question whether gross-margin leverage can outpace the SG&A build before the cash runway becomes binding.

   GuidanceNo revenue, margin or earnings guidance is provided. The only forward-looking operational statement is that 'We expect selling, general and administrative expense to moderate in the second half of fiscal 2026 resulting from a number of cost saving initiatives.' Management also states that 'based on our current business plan, we believe our current cash, cash equivalents and short-term investments and anticipated cash flow from operations will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this Quarterly Report on Form 10-Q.'

   Outlook / toneThe filing offers no revenue or earnings outlook. Using its own words, management says it 'expect[s] selling, general and administrative expense to moderate in the second half of fiscal 2026 resulting from a number of cost saving initiatives,' and that 'based on our current business plan, we believe our current cash, cash equivalents and short-term investments and anticipated cash flow from operations will be sufficient to meet our anticipated cash requirements for more than 12 months from the date of this Quarterly Report on Form 10-Q.' It cautions that operating results for the six months ended March 31, 2026 'are not necessarily indicative of the results expected for the full year ending September 30, 2026 or any interim period,' and states that achieving profitability 'will depend heavily on the success of our existing products and the development and commercialization of additional products... as well as leveraging our investment in our manufacturing infrastructure.' The revenue discussion attributes growth to increases in therapeutics, diagnostics, academic research and government, and global supply partners customers and to a higher customer count.

   Strategic priorities

   • Multi-channel commercial strategy: direct sales teams aligned to key markets plus an e-commerce platform with real-time pricing and order tracking, serving more than 3,800 customers annually.
   • Extend the silicon-based DNA synthesis platform across the 'biological continuum' into synthetic genes, NGS applications, sample preparation tools, antibody libraries and biologics discovery services.
   • Entered a February 2026 co-exclusive, royalty-bearing license (initial 7-year term) for Invenra's proprietary B-Body bispecific antibody discovery platform, plus a 6.24% fully-diluted equity stake in Invenra (total commitment $33.8 million, settled mostly in common stock).
   • Support traditional and AI-enabled therapeutics discovery, diagnostics, industrial/applied, agricultural biotech and academic research applications.
   • Cost discipline: management expects SG&A to moderate in the second half of fiscal 2026 through cost saving initiatives.
   • Regularly review acquisition and investment opportunities that meet long-term growth objectives.

   Capex plansThe company had $15.7 million in commitments for capital expenditures as of March 31, 2026; purchases of property and equipment were $17.9 million in H1 FY2026 versus $6.4 million in H1 FY2025. Capital expenditure is described as one of the primary uses of capital, alongside compensation, manufacturing costs, laboratory supplies and legal/regulatory and overhead costs. The November 13, 2025 South San Francisco lease amendment adds approximately 33,000 square feet from September 1, 2026, extends the lease to June 30, 2036, and includes a landlord tenant improvement allowance of approximately $24.4 million, with expected future cash commitments for the additional space of $11.6 million through June 30, 2036.

   Capital allocationPrimary uses of capital are 'compensation and related expenses, manufacturing costs, laboratory and related supplies, legal and other regulatory expenses and general overhead costs, including facilities costs and capital expenditures,' with $15.7 million of capital expenditure commitments at March 31, 2026. The company has historically financed operations through 'public equity raises, private placements of our convertible preferred stock, borrowings from credit facilities, proceeds from the royalty purchase agreement, sale of DNA data storage assets and revenue from our commercial operations.' The $33.8 million Invenra commitment was substantially non-cash: only $5.0 million was a cash outflow, with $28.8 million settled or to be settled through issuance of common stock (including $8.75 million recorded as a current liability). No dividends or share repurchases are disclosed; the only buybacks were de minimis share repurchases for income tax withholding.

   BacklogThe filing discloses no bookings or order-book metric. It reports $16.6 million of transaction price allocated to unsatisfied performance obligations as of March 31, 2026, which the company 'expects to recognize revenue over the next twelve months,' alongside contract liabilities (advance payments) of $7.1 million and contract assets of $8.4 million. Revenue recognized from beginning contract liabilities was $2.5 million in Q2 and $2.6 million in H1.

   Debt / leverageNo borrowings or credit facility debt are disclosed. The non-current 'liability related to the sale of future revenue' was $15.0 million at both March 31, 2026 and September 30, 2025 (proceeds of $15.0 million from XOMA in H1 FY2025). Operating lease liabilities totaled $95.8 million ($10.4 million current; weighted-average discount rate 6.9%, remaining term 14.1 years). Accrued expenses and other current liabilities of $67.8 million include litigation accruals of $20.6 million, a liability for issuance of shares of common stock of $8.75 million, and contract liabilities of $7.1 million. Total stockholders' equity was $455.1 million.

   Risk-factor changesThe filing states: 'There have been no material changes in our risk factors from those described in our Annual Report on Form 10-K' filed November 17, 2025. The substantive new risk-related developments in this 10-Q are the settlement in principle of the securities class action for approximately $17.1 million (with a probable $14.9 million insurance recovery recognized) and the continued stay of the consolidated derivative actions.

   MD&A highlights

   • Q2 FY2026 revenues rose 19.3% to $110.7 million from $92.8 million; H1 revenues rose 18.1% to $214.4 million from $181.5 million, 'driven by strong performance in DNA synthesis and protein solutions and NGS applications.'
   • Gross margin expanded to 51.6% in Q2 (from 49.6%) and 51.8% in H1 (from 49.0%), 'primarily due to increases in revenues and driving additional cost savings through continuous process improvement initiatives.'
   • Product mix: DNA synthesis and protein solutions grew 28% to $53.3 million in Q2 (48% of revenue); NGS applications grew 12% to $57.4 million (52%).
   • Volume/customer metrics: genes shipped rose 32% to ~300,000 in Q2 (571,000 in H1); customers ~2,583 vs 2,431 in the prior-year quarter.
   • Revenue by industry: therapeutics $40.8 million (37% of Q2), diagnostics $40.0 million (36%), academic research and government $12.8 million (12%), global supply partners $11.4 million (10%), industry and applied $5.8 million (5%).
   • Revenue by geography Q2: Americas $64.3 million (58%), EMEA $37.3 million (34%), APAC $9.1 million (8%).
   • R&D expense fell 18% to $19.7 million in Q2 (19% to $36.8 million in H1), 'largely attributable to the sale of our DNA data storage business in fiscal year 2025.'
   • SG&A rose 19% to $76.1 million in Q2 (22% to $145.8 million in H1) reflecting 'headcount additions and investments in our commercial organization and corporate infrastructure to support the continued growth of the business.'
   • Loss from operations widened 10.4% to $45.9 million in Q2 and 3.4% to $78.8 million in H1; net loss was $44.0 million ($0.71/share) and $74.5 million ($1.21/share), respectively.
   • Net cash used in operating activities increased 23.1% to $42.4 million in H1, primarily net loss of $74.5 million adjusted for $12.6 million D&A and $32.2 million stock-based compensation, plus $11.8 million net outflow from operating assets and liabilities.
   • Litigation settlement costs, net of recoveries, of $7.2 million recorded in the quarter related to the securities class action settlement in principle.
   • Interest income fell 39% to $1.7 million in Q2 (36% to $3.9 million in H1) on lower cash/short-term investment balances and lower interest rates.

   Key risks

   • Recurring losses and large accumulated deficit: net loss of $44.0 million in Q2 and $74.5 million in H1 FY2026, with an accumulated deficit of $1,394.1 million as of March 31, 2026; the company has 'recognized annual losses from operations since inception.'
   • Potential need for additional financing beyond the stated 12-month runway; the company says there 'can be no assurance that we will be successful in raising additional financing on terms that are acceptable to us.'
   • Pending litigation: the Peters v. Twist Bioscience securities class action settled in principle for approximately $17.1 million (presented to the Court for preliminary approval on April 30, 2026), with derivative suits (Shumacher and Sell actions) consolidated and stayed; 'the Company cannot accurately predict the ultimate outcome of this matter.'
   • Dependence on 'the success of our existing products and the development and commercialization of additional products in the therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners revenue industries as well as leveraging our investment in our manufacturing infrastructure' to reach profitability.
   • Execution and cost-control risk: SG&A grew 19-22% on commercial and infrastructure build-out even as the company targets H2 FY2026 SG&A moderation.
   • Risks cited in the forward-looking statement list include competition and rapid technology change, international expansion and evolving EU/other regulatory requirements, IT security breaches, ability to attract and retain key personnel, integration of AI/ML technologies, acquisition/investment risk, and adverse economic and market conditions.
8. 10-Q2026-02-26

   Source ↗

   No parsed narrative for this filing.

9. 8-K2026-02-17

   Source ↗

   No parsed narrative for this filing.

10. 8-K2026-02-06

    Source ↗

    No parsed narrative for this filing.

11. 8-K2026-02-02

    Source ↗

    No parsed narrative for this filing.

12. 10-Q2026-02-02

    Source ↗

    No parsed narrative for this filing.

13. 8-K2026-01-12

    Source ↗

    No parsed narrative for this filing.

14. 10-K2025-11-17

    Source ↗

    Twist Bioscience's FY2025 10-K reads as a story of a differentiated but still-unprofitable platform company making real progress on losses: revenue reached $376.6 million across healthcare ($215.1M), chemicals/materials ($93.2M), academic ($65.9M) and food/ag ($2.4M), while the net loss narrowed sharply to $77.7 million from $208.7 million and $204.6 million in the prior two years—though an accumulated deficit of $1,319.6 million underscores how much capital has been consumed. Management is confident in the 'disruptive' silicon-chip DNA synthesis platform and the antibody 'discovery trifecta,' evidenced by 442 revenue-generating partnerships (84 active, 82 with milestones/royalties), but offers no formal guidance and warns it 'may never achieve profitability.' Capital allocation is defensive: no dividend, no buyback, a $15 million XOMA royalty monetization to bring in cash, and a May 2025 spin-out of DNA data storage (Atlas) to sharpen focus—leaving the balance sheet to fund operations 'through at least the next 12 months.' For a value investor, the key questions are whether the loss trajectory keeps improving toward breakeven, whether the concentrated single-source supply and two-facility manufacturing footprint remain resilient, and how much policy risk (tariffs, the federal research-grant halt, and evolving biosecurity/export rules) pressures a customer base that is heavily academic and grant-sensitive and 42% international. Note this excerpt omits Item 7 MD&A and the financial statements, so cash position, debt terms, and detailed operating trends should be confirmed from the full filing.

    Outlook / toneManagement's tone is confident about its technology but explicitly hedged on profitability and gives no formal guidance. The filing states 'We believe Twist Bioscience is uniquely positioned to help accelerate their efforts' and calls its core 'a disruptive DNA synthesis platform,' presenting the Company as 'the only DNA synthesis provider to synthesize DNA on a silicon chip on a large commercial level.' At the same time it warns: 'We have incurred net losses in every period to date, and we expect to continue to incur significant losses as we develop our business and may never achieve profitability.' No revenue, margin, or EPS outlook is offered; the only forward-looking financial statement is that existing cash and investments should fund operations 'through at least the next 12 months.' Management flags external headwinds directly, citing that 'new U.S. federal administration has recently imposed significant new tariffs,' that 'the administration's halt on certain federal research grants may negatively impact our industry,' and that 'Any prolonged reductions in such funding could slow innovation, delay collaborations and limit the adoption of new technologies.' Overall: cautiously optimistic on platform positioning, candid about ongoing losses and policy/tariff uncertainty.

    Strategic priorities

    • Maintain and expand position as the provider of choice for high-quality, affordable synthetic DNA, RNA and proteins across multiple industries.
    • Expand antibody and protein production and broaden the array of characterization assays to support therapeutics discovery.
    • Become a leading supplier of NGS sample preparation products (liquid biopsy, MRD, agricultural and population genomics).
    • Conduct biopharma services for current customers and future partners (the 'discovery trifecta' of in vivo, in vitro and in silico antibody discovery).
    • Expand global presence and international markets.
    • Move further up the value chain from fragments to genes to preps to proteins and monetize antibody discovery via licensing fees, fee-for-service, milestones and royalties.
    • Continue research and development focused on process improvements, proprietary enzymes, AI applications, and new products including mRNA and proteins.

    Capex plansNo specific capital expenditure program, dollar amount, or timeline is disclosed. The filing states that continued growth 'could require significant capital expenditures,' that transitioning to new/upgraded operational and IT systems 'requires significant capital investments and personnel resources,' and that the Company expects to continue incurring expenses for system improvements and upgrades, with cash expected to cover 'capital expenditure requirements' for at least the next 12 months.

    Capital allocationNo dividends: 'We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future,' with earnings retained for operations and general corporate purposes. No share repurchase program is disclosed. The Company monetized part of its antibody pipeline economics in October 2024, when XOMA Royalty paid Twist $15 million cash for 50% of future milestone and royalty payments from existing collaborations as of signing (Twist retains all upfront, service and other revenue plus half of future milestones/royalties). It also retains an equity interest plus potential milestone and royalty payments from the Atlas Data Storage spin-out. M&A is discussed only generically as a possible use of capital ('we may enter into transactions to acquire other businesses, products or technologies'), with no specific targets, amounts, or appetite committed.

    BacklogNo backlog, bookings, or order-book metrics are disclosed. As of September 30, 2025, the Company had signed 442 revenue-generating partnerships, with 1,182 completed programs and 84 active programs, 82 of which include milestones and/or royalties.

    Debt / leverageNo debt balances, maturities, or leverage ratios are disclosed in the provided text. A risk factor states that existing cash, cash equivalents and short-term investments are expected to fund 'our planned operating expenses, capital expenditure requirements and debt service payments through at least the next 12 months,' implying the Company carries some debt-service obligations.

    Risk-factor changesThe excerpt does not present a year-over-year comparison, so changes versus the prior 10-K cannot be confirmed from this text. Notable/newly emphasized themes include: risks tied to integrating AI and machine learning and the 'rapidly evolving regulatory landscape surrounding AI'; tariff and trade-policy exposure plus the federal research grant halt; the rescission of the FDA's LDT Final Rule (vacated March 31, 2025 and rescinded August 6, 2025); risks specific to the May 2025 spin-out of the DNA data storage business to Atlas Data Storage, including transition services and potential failure to realize anticipated benefits; and the XOMA Royalty monetization. The summary of financial-reporting control risk notes prior material weaknesses disclosed for FY2020-FY2023 that 'each...has been remediated,' with management concluding ICFR was effective as of September 30, 2024 and September 30, 2025.

    MD&A highlights

    • Fiscal 2025 revenue was $376.6 million, comprising $215.1 million from healthcare, $93.2 million from chemicals/materials, $65.9 million from academic research, and $2.4 million from food/agriculture.
    • Net loss of $77.7 million for FY2025, a sharp narrowing from $208.7 million in FY2024 and $204.6 million in FY2023.
    • Accumulated deficit of $1,319.6 million as of September 30, 2025.
    • Served more than 3,800 customers in fiscal 2025; 42% of revenue was generated outside the United States (vs. 40% in both FY2024 and FY2023).
    • Note: the provided text contains the Business and Risk Factors sections only; the full MD&A (Item 7) was not included in the excerpt.

    Key risks

    • Net losses in every period to date; expectation of continued significant losses and possible failure to ever achieve profitability.
    • Dependence on a single-source supplier for a critical component of the DNA synthesis process (no internal manufacturing capability for it).
    • Intense competition across synthetic biology, NGS sample prep, and antibody discovery from larger, better-resourced players.
    • Customer concentration risk; loss of a limited number of large customers would harm revenue, cash flows and reputation.
    • Cybersecurity and IT system risks, including AI-enabled attacks and reliance on internally managed e-commerce platform.
    • Substantial dependence on the success of synthetic DNA products for substantially all revenue.
    • Potential need for additional financing; terms may not be available or may be dilutive/restrictive.
    • Uncertainty in protecting and enforcing intellectual property; extensive patent litigation exposure.
    • Dependence on senior management (including CEO Dr. Emily Leproust) and key scientific/engineering personnel.
    • Risks from strategic transactions, acquisitions, collaborations and investments, including the May 2025 spin-out of DNA data storage to Atlas Data Storage.
    • Macro/geopolitical risk: new U.S. tariffs and retaliatory trade actions, supply-chain disruption, and a government 'halt on certain federal research grants' that could slow demand.
    • Manufacturing concentration in two facilities (Wilsonville, OR and South San Francisco, CA) exposed to natural disasters, earthquakes, fire and weather.
    • Export-control and biosecurity/FSAP compliance risk; evolving nucleic-acid synthesis screening requirements.
    • International operating risks, including FCPA/UK Anti-Bribery compliance (42% of FY2025 revenue was non-U.S.).
    • Rapidly changing technology, including AI potentially disrupting synthetic biology and reducing demand for certain gene synthesis.
15. 8-K2025-11-14

    Source ↗

    No parsed narrative for this filing.

Extracted facts only — this page reproduces the stored filing summaries; it computes no valuation. Not investment advice.